Standing Order
All companies

Biotech

Novo Nordisk A/S

NVONYSEdiversified
Market cap$126B
Conviction4/ 5
HQBagsvaerd, Denmark
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$37.82

-48.1%

Thesis

Novo Nordisk markets the semaglutide products Ozempic and Wegovy for type 2 diabetes and obesity. As a diversified company, its incretin franchise sits alongside a broader diabetes and metabolic portfolio.

Catalysts

  • Semaglutide supply and manufacturing expansion
  • Next-generation incretin clinical readouts
  • Label expansions for Ozempic and Wegovy

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 19
    Trial readoutClinicalTrials.gov

    Phase 2 trial NCT06409130 of NNC0194-0499, cagrilintide and semaglutide in alcohol-related liver disease completed.

  • Nov 19
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT06065540 of CagriSema vs semaglutide/cagrilintide/placebo in T2D completed.

  • Nov 16
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT06588504 for dasiglucagon vs glucagon in hypoglycemia completed (Japan, T1D adults/adolescents)

  • Nov 16
    OtherClinicalTrials.gov

    Phase 3 trial NCT07220759 (cagrilintide, overweight/obesity + T2D) status updated to ACTIVE_NOT_RECRUITING.

  • Nov 16
    Trial readoutClinicalTrials.gov

    Phase 3 trial NCT04775082 (SCALE KIDS) for weight management in children with obesity updated to ACTIVE_NOT_RECRUITING status.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07931573 (AMBITION 3) for Zenagamtide vs semaglutide in T2D, status NOT_YET_RECRUITING.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Novo Nordisk Phase 3 trial NCT07931495 of Zenagamtide in Type 2 diabetes, status NOT_YET_RECRUITING.

  • Nov 12
    Trial initiationClinicalTrials.gov

    Phase 3 trial NCT07931599 initiated (NOT_YET_RECRUITING) comparing Zenagamtide vs semaglutide in T2D patients on metformin/SGLT2i.

Not financial advice — research and opinion only. Disclosures